Oncolytics Biotech (NASDAQ:ONCY – Get Free Report) and Spyre Therapeutics (NASDAQ:SYRE – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings. Insider and Institutional Ownership 1.1% of Oncolytics […]
HC Wainwright restated their buy rating on shares of Oncolytics Biotech (NASDAQ:ONCY – Free Report) in a report released on Friday morning, Benzinga reports. HC Wainwright currently has a $5.00 price target on the stock. Separately, Cantor Fitzgerald reissued an overweight rating on shares of Oncolytics Biotech in a report on Friday, January 12th. Read […]
HC Wainwright restated their buy rating on shares of Oncolytics Biotech (NASDAQ:ONCY – Free Report) in a research note released on Thursday, Benzinga reports. The firm currently has a $5.00 target price on the stock. Oncolytics Biotech Trading Down 3.8 % Oncolytics Biotech stock opened at $1.26 on Thursday. The stock has a market cap […]
Oncolytics Biotech (NASDAQ:ONCY – Get Free Report) and Roivant Sciences (NASDAQ:ROIV – Get Free Report) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, risk, earnings and dividends. Earnings & Valuation This table compares Oncolytics Biotech […]
Oncolytics Biotech (NASDAQ:ONCY – Free Report) had its price objective cut by HC Wainwright from $15.00 to $5.00 in a research note published on Monday, Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Oncolytics Biotech’s Q4 2023 earnings at ($0.09) EPS, FY2023 earnings at ($0.36) EPS, […]